Key result
Stem cell therapy may decrease fibrosis and improve microcirculation, potentially serving as the first etiology-based therapy for heart failure with preserved ejection fraction.
Why the study?
Heart failure with preserved ejection fraction is an increasing clinical problem without efficient treatment available, though stem cell transplantation may offer an etiology-based therapy.
Answers are grounded in this paper and cite their sources.
This review highlights the theoretical potential of stem cell therapy as a novel, etiology-based treatment for HFpEF by targeting fibrosis and microcirculation.
Heart failure, a leading cause of hospitalizations and deaths, is a major clinical problem. In recent years, the increasing incidence of heart failure with preserved ejection fraction (HFpEF) has been observed. Despite extensive research, there is no efficient treatment for HFpEF available. However, a growing body of evidence suggests stem cell transplantation, due to its immunomodulatory effect, may decrease fibrosis and improve microcirculation and therefore, could be the first etiology-based therapy of the disease. In this review, we explain the complex pathogenesis of HFpEF, delineate the beneficial effects of stem cells in cardiovascular therapy, and summarize the current knowledge concerning cell therapy in diastolic dysfunction. Furthermore, we identify outstanding knowledge gaps that may indicate directions for future clinical studies.
No takes yet. Share an insight, caveat, or question.
Domaszk et al. (2023) conducted a review in Heart failure with preserved ejection fraction (HFpEF). Stem cell therapy was evaluated. Stem cell therapy may decrease fibrosis and improve microcirculation, potentially serving as the first etiology-based therapy for heart failure with preserved ejection fraction.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: